PI3K and mTOR signalling pathways: Perspectives for rapamycin and its derivatives as antineoplastic targeted therapies;Voies de signalisation de la PI3K et de mTOR: Perspectives de l'utilisation de la rapamycine et de ses dérivés en thérapie antitumorale ciblée

Bulletin du Cancer

Volumn 93, Issue SPEC. ISS. APR., 2006, Pages 31-40

  Dreyer, Chantal ^a   Faivre, Sandrine ^a   Raymond, Eric ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

mTOR; PI3K; Rapamycine; Targeted therapies

Indexed keywords

ANTINEOPLASTIC AGENT; AP 23573; EVEROLIMUS; HETERODIMER; IMMUNOSUPPRESSIVE AGENT; MACROLIDE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN; TEMSIROLIMUS;

APOPTOSIS; ARTICLE; BRAIN DEVELOPMENT; CELL CYCLE; CELL FUNCTION; DOSE RESPONSE; DRUG INHIBITION; DRUG METABOLISM; DRUG SCREENING; DRUG TARGETING; GENE CONTROL; GENE FUNCTION; GENETIC TRANSDUCTION; HUMAN; KIDNEY GRAFT REJECTION; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PANCREAS CARCINOMA; SKIN MANIFESTATION; TOXICITY;

EID: 33745459302     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
2. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003; 35: 7S-14S.
3. Paez J, Sellers WR. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat Res 2003; 115: 145-67.
4. Borlado LR, Redondo C, Alvarez B, et al. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J 2000; 14: 895-903.
5. Choe G, Horvath S, Cloughesy TF, et al. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003; 63: 2742-6.
6. Neve RM, Holbro T, Hynes NE. Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells. Oncogene 2002; 21: 4567-76.
7. Philp AJ, Campbell IG, Leet C, et al. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001; 61: 7426-9.
8. Grant S, Qiao L, Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci 2002; 7: 376-89.
9. Krasilnikov MA. Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. Biochemistry 2000; 65: 59-67.
10. Kozma SC, Thomas G. Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K. Bioassays 2002; 24: 65-71.
11. Mhashilkar AM, Stewart AL, Sieger K, et al. MDA-7 negatively regulates the beta-catenin and PI3K signaling pathways in breast and lung tumor cells. Mol Ther 2003; 8: 207-19.
12. Edinger AL, Thompson CB. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 2002; 13: 2276-88.
13. Siebert R, Gesk S, Harder S, et al. Deletions in the long arm of chromosome 10 in lymphomas with t (14; 18): a pathogenetic role of the tumor supressor genes PTEN/MMAC1 and MXI1? Blood 1998; 92: 4487-9.
14. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16: 64-7.
15. Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998; 7: 507-15.
16. Davies MA, Lu Y, Sano T, et al. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res 1998; 58: 5285-90.
17. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98: 10314-9.
18. Ui M, Okada T, Hazeki K, et al. Wortmannin as a unique probe for an intracellular signalling protein, phosphoinositide 3-kinase. Trends Biochem Sci 1995; 20: 303-7.
19. Hazeki O, Hazeki K, Katada T, et al. Inhibitory effect of wortmannin on phosphatidylinositol 3-kinase-mediated cellular events. J Lipid Mediat Cell Signal 1996; 14: 259-61.
20. Sabers CJ, Martin MM, Brunn GJ, et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995; 270: 815-22.
21. Lorenz MC, Heitman J. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. J Biol Chem 1995; 270: 27531-7.
22. Wiederrecht GJ, Sabers CJ, Brunn GJ, et al. Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. Prog Cell Cycle Res 1995; 1: 53-71.
23. Dos Sarbassov D, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14: 1296-302.
24. Dennis PB, Jaeschke A, Saitoh M, et al. Mammalian TOR: a homeostatic ATP sensor. Science 2001; 294: 1102-5.
25. Gingras AC, Kennedy SG, O'Leary MA, et al. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt (PKB) signaling pathway. Genes Dev 1998; 12: 502-13.
26. Heesom KJ, Denton RM. Dissociation of the eukaryotic initiation factor-4E/4E-BP1 complex involves phosphorylation of 4E-BP1 by an mTOR-associated kinase. FEBS Lett 1999; 457: 489-93.
27. Hara K, Yonezawa K, Weng QP, et al. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem 1998; 273: 14484-94.
28. McLeod LE, Proud CG. ATP depletion increases phosphorylation of elongation factor eEF2 in adult cardiomyocytes independently of inhibition of mTOR signalling. FEBS Lett 2002; 531: 448-52.
29. Li B, Desai SA, MacCorkle-Chosnek RA, et al. A novel conditional Akt 'survival switch' reversibly protects cells from apoptosis. Gene Ther 2002; 9: 233-44.
30. Castedo M, Roumier T, Blanco J, et al. Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope. EMBO J 2002; 21: 4070-80.
31. Takuwa N, Fukui Y, Takuwa Y. Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70 (S6K)-independent signaling in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol 1999; 19: 1346-58.
32. Pene F, Claessens YE, Muller O, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002; 21: 6587-97.
33. Xu G, Kwon G, Cruz WS, et al. Metabolic regulation by leucine of translation initiation through the mTOR-signaling pathway by pancreatic beta-cells. Diabetes 2001; 50: 353-60.
34. Tang SJ, Reis G, Kang H, et al. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci USA 2002; 99: 467-72.
35. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot 1975; 28: 721-6.
36. Singh K, Sun S, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. IV Mechanism of action. J Antibiot 1979; 32: 630-45.
37. Baker H, Sidorowicz A, Sehgal SN, et al. Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. J Antibiot 1978; 31: 539-45.
38. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot 1975; 28: 727-32.
39. Fruman DA, Wood MA, Gjertson CK, et al. FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells. Eur J Immunol 1995; 25: 563-71.
40. Yatscoff RW, LeGatt DF, Kneteman NM. Therapeutic monitoring of rapamycin: a new immunosuppressive drug. Ther Drug Monit 1993; 15: 478-82.
41. Davies CB, Madden RL, Alexander JW, et al. Effect of a short course of rapamycin, cyclosporin A, and donor-specific transfusion on rat cardiac allograft survival. Transplantation 1993; 55: 1102-7.
42. Kahan BD. Optimization of cyclosporine therapy. Transplant Proc 1993; 25: 5-9.
43. Trepanier DJ, Gallant H, Legatt DF, et al. Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update. Clin Biochem 1998; 31: 345-51.
44. Ochiai T, Gunji Y, Nagata M, et al. Effects of rapamycin in experimental organ allografting. Transplantation 1993; 56: 15-9.
45. Qi S, Xu D, Peng J, et al. Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey. Transplantation 2000; 69: 1275-83.
46. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999; 99: 2164-70.
47. Sousa JE, Sousa AG, Costa MA, et al. Use of rapamycin-impregnated stents in coronary arteries. Transplant Proc 2003; 35: 165S-170S.
48. Poon M, Marx SO, Gallo R, et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996; 98: 2277-83.
49. Mohacsi PJ, Tuller D, Hulliger B, et al. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 1997; 16: 484-92.
50. Yatscoff RW, Wang P, Chan K, et al. Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug Monit 1995; 17: 666-71.
51. Yatscoff RW. Pharmacokinetics of rapamycin. Transplant Proc 1996; 28: 970-3.
52. Mignat C. Clinically significant drug interactions with new immunosuppressive agents. Drug Saf 1997; 16: 267-78.
53. Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001; 40: 573-85.
54. Brattstrom C, Tyden G, Sawe J, et al. A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc 1996; 28: 985-6.
55. Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation 2001; 72: 1181-93.
56. Reitamo S, Spuls P, Sassolas B, et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 2001; 145: 438-45.
57. Busca R, Bertolotto C, Ortonne JP, et al. Inhibition of the phosphatidylinositol 3-kinase/p70 (S6)-kinase pathway induces B16 melanoma cell differentiation. J Biol Chem 1996; 271: 31824-30.
58. Eng CP, Sehgal SN, Vezina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot 1984; 37: 1231-7.
59. Grewe M, Gansauge F, Schmid RM, et al. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res 1999; 59: 3581-7.
60. Hosoi H, Dilling MB, Shikata T, et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999; 59: 886-94.
61. Shi Y, Frankel A, Radvanyi LG, et al. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 1995; 55: 1982-8.
62. Calastretti A, Bevilacqua A, Ceriani C, et al. Damaged microtubules can inactivate BCL-2 by means of the mTOR kinase. Oncogene 2001; 20: 6172-80.
63. Humar R, Kiefer FN, Berns H, et al. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 2002; 16: 771-80.
64. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8 : 128-35.
65. Geoerger B, Kerr K, Tang CB, et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 2001; 61: 1527-32.
66. Gibbons JJ, Discafani C, Peterson R. The effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells in vitro and in nude mouse xenograft in vivo. Proc Am Assoc Cancer Res 2000; 40: 301.
67. Ito D, Fujimoto K, Doi R, et al. mTOR, a novel target in pancreatic cancer: The effect of CCI-779 in preclinical models. Proc Am Assoc Cancer Res 2004: 45; (abstract 3886).
68. Wu L, Birle D, Tannock I. Effects of the mTOR inhibitor CCI-779 used alone or during chemotherapy on human prostate cancer xenografts. Proc Am Assoc Cancer Res 2004; 45; (abstract 3849).
69. Nathan C-A, Amirghahari N, Sibley D, et al. In vivo and in vitro effect of CCI-779 a rapamycin analogue on HNSCC. Proc Am Assoc Cancer Res 2004; 45; (abstract 3688).
70. Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8: 249-58.
71. Elit L. CCI-779 Wyeth. Curr Opin Investig Drugs 2002; 3: 1249-53.
72. Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs 2002; 3: 295-304.
73. Raymond E, Alexandre J, Depenbrock H, et al. CCI-779, a rapamycin analog with antitumor activity: a phase I study utilizing a weekly schedule. Proc Am Soc Clin Onco 2000; (abstract 728).
74. Hidalgo M, Rowinsky EK, Erlichman C, et al. CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: a phase I study. Proc Am Soc Clin Oncol 2000; 19; (abstract 726).
75. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22: 2336-47.
76. Peralba JM, DeGraffenried L, Friedrichs W, et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 2003; 9: 2887-92.
77. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36-42.
78. Schuurman HJ, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997; 64: 32-5.
79. O'Reilly T, Vaxelaire J, Muller M, et al. In vivo activity of RAD 001, an orally active rapamycin derivative, in experimental tumor models. Proc Am Assoc Cancer Res 2002: 43; (abstract 359).
80. Lane H, Schnell C, Theuer A, et al. Antiangiogenetic activity of RAD 001, an orally active anticancer agent. Proc Am Assoc Cancer Res 2002; 43; (abstract 922).
81. Majewski M, Korecka M, Joergensen J, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003; 75: 1710-7.
82. Majewski M, Korecka M, Kossev P, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000; 97: 4285-90.
83. Kahan BD, Wong RL, Carter C, et al. A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1999; 68: 1100-6.
84. Metcalf C, Bohacek R, Rozamus L, et al. Structure-based design of AP23573, a phosphorus-containing analog of rapamycin for anti-tumor therapy. Proc Am Assoc Cancer Res 2004; 45; (abstract 2476).
85. Rivera V, Tang H, Metcalf C, et al. Anti-proliferative activity of the mTOR inhibitor AP23573 in combination with cytotoxic and targeted agents. Proc Am Assoc Cancer Res 2004; 45; (abstract 3887).
86. Aguirre D, Boya P, Bellet D, et al. Bcl-2 and CCND1/CDK4 as molecular markers of the cellular effects of mTOR inhibitors in human ovarian carcinomas cells. Apoptosis 2004; 9: 797-805.
87. Degrafenried L, Friedrichs W, Fulcher L, et al. The mTOR inhibitor, CCI-779, restores tamoxifen response in breast cancer cells with high Akt activity. Proc 14th NCI-EORTC-AACR symposium on molecular targets and cancer therapeutics. Eur J Cancer 2002: S158; (abstract 528).
88. Rudloff J, Boulay A, Zumstein-Mecker S, et al. The mTOR pathway in estrogen response: A potential for combining the rapamycin derivative RAD001 with the aromatase inhibitor Letrozole (Femara®) in breast carcinoma. Proc Am Assoc Cancer Res 2004: 45; (abstract 5619).
89. Bianco R, Shin I, Ritter CA, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003; 22: 2812-22.
90. Van Oosterom A, Dumez H, Desai J, et al. Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (RAD001) and imatinib mesylate in patients with gastrointestinal stromal tumor (GIST) refractory to IM. Proc Am Soc Clin Oncol 2004; (abstract 3002).